Clinical Trial

Bioavailability and Bioequivalence Study of Extended Release Torsemide and Spironolactone

Completed Phase 3
View on ClinicalTrials.gov →
Summary
To study intrasubject variability and steady-state pharmacokinetics of multiple-doses of Extended Release Torsemide and Spironolactone Fixed Dose Combination (FDC) tablets given together in healthy adult subjects.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-06-30.
Status change: Recruiting → Completed 2026-03-05
Trial Details
NCT Number NCT07046975
Lead Sponsor Sarfez Pharmaceuticals, Inc.
Conditions Bioavailability Heathy Volunteers
Enrollment 24 participants
Start Date 2025-06-15
Primary Completion 2026-02-28 (estimated)
Study Completion 2026-02-28 (estimated)
Updated on ClinicalTrials.gov 2026-03-09